What’s new

• Consolidated revenue grew ~16% YoY, slower than Q4FY26's 23.6% growth.
• TruHealth Wellness and Specialty segments are the fastest growing.
• B2C and B2B volumes both rose; EBITDA margins improved YoY and were stable QoQ.

Why it matters

The deceleration from Q4's pace is notable, but margin improvement suggests cost discipline. With no absolute figures, the audited results will determine whether the slowdown is seasonal or structural.

What we’re watching

• Full Q1FY27 financials with absolute revenue and profit numbers.
• Segment-level profitability, especially for Wellness and Specialty.
• Whether B2B wallet share gains continue to offset B2C seasonality.

The full read

Metropolis Healthcare's Q1FY27 business update shows revenue growing ~16% year-on-year, driven by patient volumes and a favourable product mix. That is a deceleration from Q4FY26's 23.6% growth, but EBITDA margins improved YoY and held steady QoQ – a sign of cost discipline. The fastest growth came from the TruHealth Wellness and Specialty segments, while both B2C and B2B channels posted higher volumes. The filing is a routine early glimpse: no absolute numbers, no guidance revision. The open question is whether the slowdown is seasonal or structural. Full results after board approval will tell.

Primary source: BSE · NSE